Infectious disease
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Roche and Atea Pharmaceuticals are partnering to develop, manufacture and distribute AT-527, Atea’s experimental antiviral drug against COVID-19.
Shares of AstraZeneca dropped slightly Wednesday afternoon following reports that a patient participating in the Brazilian arm of the company’s global Phase III study has died.
As we resign ourselves to the fact that the epic SARS-CoV-2 virus that dominated 2020 is going to stubbornly follow us into 2021, we need to learn how to co-exist in temporary tolerance, at least until we have an effective vaccine.
The U.S. arm of the trial has been paused for more than a month while the U.S. Food and Drug Administration investigates a serious illness that occurred in a patient who received the experimental treatment.
Stephane Bancel, chief executive officer of Moderna, told analysts and journalists at a Wall Street Journal’s Tech Live event on Monday that the FDA requires enough safety and efficacy data, and he believes that they will have that in the later part of November.
In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
Dr. Monica Gandhi, MD, an infectious diseases doctor and professor of medicine at UC San Francisco, poses the hypothesis that masks and other social distancing measures may reduce the viral inoculum – or amount – of the SARS-CoV-2 we contract.
They believe that by inhibiting factor D, it would reduce the inflammatory reactions that make COVID-19 so deadly.
PRESS RELEASES